Literature DB >> 21632859

Is cytomegalovirus a therapeutic target in glioblastoma?

John H Sampson1, Duane A Mitchell.   

Abstract

Several investigators have now demonstrated the expression of genes unique to cytomegalovirus (CMV) in malignant gliomas. Many of these genes promote oncogenesis, alter tumor microenvironment, and serve as immunologic targets. Is the level of CMV infection within tumor cells sufficient to drive important oncogenic or immunosuppressive processes? Can CMV serve as a target for therapeutic intervention?

Entities:  

Mesh：

Year:  2011        PMID： 21632859     DOI： 10.1158/1078-0432.CCR-11-0992

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  T cell engineering as therapy for cancer and HIV: our synthetic future.

Authors:  Carl H June; Bruce L Levine
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

2.  RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions.

Authors:  E Xiaofei; Bradford M Stadler; Michelle Debatis; Shixia Wang; Shan Lu; Timothy F Kowalik
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 4.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.

Authors:  Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter
Journal:  Expert Rev Mol Diagn       Date:  2014-05       Impact factor: 5.225

Review 5.  Vaccine-based immunotherapy for glioblastoma.

Authors:  Alissa A Thomas; Jan L Fisher; Marc S Ernstoff; Camilo E Fadul
Journal:  CNS Oncol       Date:  2013-07

6.  Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.

Authors:  Reena P Thomas; Lawrence Recht; Seema Nagpal
Journal:  Clin Pharmacol       Date:  2012-12-27

7.  Perspectives on investigational drugs and immunotherapies for glioblastoma.

Authors:  Julie J Miller; William T Curry; Dan P Cahill; Jörg Dietrich
Journal:  Expert Opin Investig Drugs       Date:  2016-09       Impact factor: 6.498

8.  Mutations in glioblastoma oncosuppressive pathways pave the way for oncomodulatory activity of cytomegalovirus.

Authors:  Todd C Hollon; Richard L Price; Chang-Hyuk Kwon; E Antonio Chiocca
Journal:  Oncoimmunology       Date:  2013-07-09       Impact factor: 8.110

9.  Role of infectious agents in the carcinogenesis of brain and head and neck cancers.

Authors:  Kenneth Alibek; Ainur Kakpenova; Yeldar Baiken
Journal:  Infect Agent Cancer       Date:  2013-02-02       Impact factor: 2.965

Review 10.  Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.

Authors:  Niklas Thon; Simone Kreth; Friedrich-Wilhelm Kreth
Journal:  Onco Targets Ther       Date:  2013-09-27       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.